Login to Your Account



IN THE CLINIC NEWS

Claiming a world-first, Chinese researchers have treated a spinal cord injury patient using a collagen scaffold loaded with mesenchymal stem cells in a trial to test the safety and efficacy of the procedure.

An internationally sponsored report has called for a new culture to make the open sharing of clinical trials data the norm, saying there is an unprecedented opportunity to advance the world's health by doing so.
Argos Therapeutics Inc. shares (NASDAQ:ARGS) fell 32.3 percent to $6.51 Friday – dipping below the company's $8 February 2014 initial public offering price – after top-line data from a phase IIb study showed that AGS-004, the company's personalized immunotherapy for HIV, failed to reduce median viral load more than a placebo in HIV-infected patients.
More IN THE CLINIC Headlines

Cast Your Vote

Has biotech’s bubble burst?: